Lupus & antiphospholipid syndrome
Comparative efficacy of tacrolimus-based induction therapy with and without mycophenolate mofetil in lupus nephritis: A target trial emulation study
Main finding · Total renal responseResult — go to the resultIPTW-adjusted OR 2.84 CI 1.31–6.35Authors' conclusion
In patients with proliferative LN, TAC + MMF + GC therapy was associated with a significantly higher 12-month renal response than TAC + GC.
Study context
- Population
- Patients with biopsy-proven proliferative lupus nephritis (LN) who received tacrolimus (TAC)-based induction therapy
- Participants
- 115 patients
- Exposure
- TAC + mycophenolate mofetil (MMF) + GC vs TAC + GC for induction of remission in proliferative LN
- TAC + MMF + GCn = 67
- TAC + GCn = 48reference
- Outcome
- Total renal response (complete or partial renal response)
- Follow-up
- 12 months
Methodological detailsinverse probability of treatment weighting (IPTW), binary logistic regression
- Inverse probability of treatment weighting (IPTW)
- Binary logistic regression
Main finding
Total renal response
IPTW-adjusted OR
2.84
CI 1.31–6.35
Events by group
TAC + MMF + GCvs TAC + GC
IPTW-adjusted OR 2.84 (CI 1.31–6.35)
As reported in the abstract
Observational data: associations, not effects.
Safety
Events
| Outcome | TAC + GC | TAC + MMF + GC |
|---|---|---|
| Adverse drug reactions | 7 | 11 |
Original publication
Comparative efficacy of tacrolimus-based induction therapy with and without mycophenolate mofetil in lupus nephritis: A target trial emulation study. Lupus. Published 3 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →